News

U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims

The U.S. Food and Drug Administration issued warning letters to Eli Lilly , Novo Nordisk and telehealth firm Hims & Hers ...

The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...